Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

VYNE Therapeutics Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW HAVEN, CONN.--(BUSINESS WIRE)--YARROW BIOSCIENCE, INC. (YARROW OR THE COMPANY) (NASDAQ: YARW), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING TRANSFORMATIVE THERAPIES FOR AUTOIMMUNE THYROID DISEASES, TODAY ANNOUNCED THE COMPLETION OF ITS MERGER WITH VYNE THERAPEUTICS INC. (VYNE), AND THE PREVIOUSLY ANNOUNCED PRIVATE FINANCINGS TOTALING APPROXIMATELY $200 MILLION. THE COMBINED COMPANY WILL OPERATE AS YARROW BIOSCIENCE, INC., WITH ITS SHARES EXPECTED TO BEGIN TRADING ON TH.

YARROW BIOSCIENCE ANNOUNCES CLOSING OF MERGER WITH VYNE THERAPEUTICS AND INITIATION OF DOSING IN PHASE 2A/2B TRIAL OF YB-101, A POTENTIAL FIRST-IN-CLASS TREATMENT FOR GRAVES' DISEASE AND THYROID EYE DISEASE

NEW YORK, JULY 23, 2026 (GLOBE NEWSWIRE) -- VYNE THERAPEUTICS INC. (NASDAQ: VYNE) (VYNE OR THE COMPANY) TODAY ANNOUNCED THAT ITS PREVIOUSLY ANNOUNCED SPECIAL CASH DIVIDEND (THE CASH DIVIDEND), DECLARED IN CONNECTION WITH THE TERMS AND CONDITIONS OF THE AGREEMENT AND PLAN OF MERGER AND REORGANIZATION, ENTERED INTO ON DECEMBER 17, 2025, AS AMENDED (THE MERGER AGREEMENT), WITH YARROW BIOSCIENCE, INC. (YARROW) AND YELLOW MERGER SUB CORP., WAS DISTRIBUTED, IN CASH, ON JULY 23, 2026 TO VYNE'S STOCKHOLDERS OF RECORD AS OF JULY 22, 2026 (THE RECORD DATE), SUBJECT TO THE NASDAQ DUE BILL PROCEDURES DESCRIBED BELOW, BASED ON THEIR HOLDINGS AS OF THE RECORD DATE AND DURING THE DUE BILL PERIOD (AS DEFINED BELOW) AND PRIOR TO THE REVERSE STOCK SPLIT.

VYNE THERAPEUTICS PROVIDES UPDATE REGARDING CASH DIVIDEND, REVERSE STOCK SPLIT AND ANTICIPATED TIMING OF CLOSING OF THE PROPOSED MERGER WITH YARROW BIOSCIENCE

NEW YORK, JULY 21, 2026 (GLOBE NEWSWIRE) -- VYNE THERAPEUTICS INC. (NASDAQ: VYNE) (VYNE OR THE COMPANY) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS APPROVED A REVERSE STOCK SPLIT OF VYNE'S COMMON STOCK AT A RATIO OF 1-FOR-50 IN CONNECTION WITH THE ANTICIPATED CLOSING OF THE PROPOSED MERGER (THE MERGER) WITH YARROW BIOSCIENCE, INC. (YARROW). THE REVERSE STOCK SPLIT WAS PREVIOUSLY APPROVED BY VYNE'S STOCKHOLDERS AT VYNE'S SPECIAL MEETING IN LIEU OF THE ANNUAL MEETING OF STOCKHOLDERS HELD ON JULY 16, 2026 (THE SPECIAL MEETING).

VYNE THERAPEUTICS ANNOUNCES 1-FOR-50 REVERSE STOCK SPLIT AND PROVIDES UPDATE REGARDING SPECIAL DIVIDEND IN CONNECTION WITH THE PROPOSED MERGER WITH YARROW BIOSCIENCE

AGGREGATE CASH DIVIDEND OF AN ESTIMATED $16.5 MILLION, OR AN ESTIMATED $0.38 PER SHARE AGGREGATE CASH DIVIDEND OF AN ESTIMATED $16.5 MILLION, OR AN ESTIMATED $0.38 PER SHARE

VYNE THERAPEUTICS DECLARES SPECIAL CASH DIVIDEND IN CONNECTION WITH THE PROPOSED MERGER WITH YARROW BIOSCIENCE

NEW YORK, DEC. 17, 2025 (GLOBE NEWSWIRE) -- VYNE THERAPEUTICS INC. (NASDAQ: VYNE) (VYNE) AND YARROW BIOSCIENCE, INC. (YARROW) TODAY ANNOUNCED THAT THEY HAVE ENTERED INTO A DEFINITIVE MERGER AGREEMENT PURSUANT TO WHICH THE COMPANIES WILL COMBINE IN AN ALL-STOCK TRANSACTION (THE MERGER). UPON COMPLETION OF THE MERGER, THE COMBINED COMPANY EXPECTS TO OPERATE AS YARROW BIOSCIENCE, INC. AND TRADE ON NASDAQ UNDER THE TICKER SYMBOL YARW. FOLLOWING COMPLETION OF THE MERGER, THE COMBINED COMPANY PLANS TO FOCUS ON ADVANCING YB-101 (ALSO KNOWN AS GS-098), A CLINICAL-STAGE, POTENTIALLY FIRST-IN-CLASS TSHR ANTIBODY FOR THE TREATMENT OF GD AND TED.

VYNE THERAPEUTICS AND YARROW BIOSCIENCE ANNOUNCE MERGER AGREEMENT

COMPANY IS PROGRESSING ITS PREVIOUSLY INITIATED STRATEGIC REVIEW EVALUATING A RANGE OF OPTIONS TO MAXIMIZE SHAREHOLDER VALUE, INCLUDING ASSESSMENT OF INTERNAL PIPELINE OPPORTUNITIES AND BROADER STRATEGIC ALTERNATIVES 12-WEEK, NON-CLINICAL TOXICOLOGY STUDY OF VYN202 IN DOGS TO REMEDY THE PARTIAL HOLD IN MALE CLINICAL SUBJECTS IS ONGOING; COMPANY CONTINUES TO EVALUATE POTENTIAL OPPORTUNITIES FOR VYN202 AS A TREATMENT FOR SERIOUS, IMMUNE-MEDIATED DISEASES CASH RUNWAY INTO FIRST HALF OF 2027 BASED ON PREVIOUSLY ANNOUNCED COST REDUCTIONS BRIDGEWATER, N.J., NOV. 06, 2025 (GLOBE NEWSWIRE) -- VYNE THERAPEUTICS INC. (NASDAQ: VYNE) (VYNE OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING DIFFERENTIATED THERAPIES TO TREAT INFLAMMATORY AND IMMUNE-MEDIATED CONDITIONS WITH HIGH UNMET NEED, TODAY REPORTED FINANCIAL RESULTS AS OF AND FOR THE QUARTER ENDED SEPTEMBER 30, 2025, AND PROVIDED A BUSINESS UPDATE.

VYNE THERAPEUTICS REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIDGEWATER, N.J., AUG. 14, 2025 (GLOBE NEWSWIRE) -- VYNE THERAPEUTICS INC. (NASDAQ: VYNE) (VYNE OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING DIFFERENTIATED THERAPIES TO TREAT CHRONIC INFLAMMATORY AND IMMUNE-MEDIATED CONDITIONS WITH HIGH UNMET NEED, TODAY REPORTED FINANCIAL RESULTS AS OF AND FOR THE QUARTER ENDED JUNE 30, 2025.

VYNE THERAPEUTICS REPORTS 2025 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

TRIAL DID NOT MEET PRIMARY ENDPOINT OR KEY SECONDARY ENDPOINT OF F-VASI50 AND F-VASI75 NOMINALLY STATISTICALLY SIGNIFICANT EFFECTS OBSERVED IN KEY SECONDARY AND EXPLORATORY ENDPOINTS OF CHANGE FROM BASELINE IN F-VASI AND T-VASI AT 3% CONCENTRATION COMPANY WILL TERMINATE EXTENSION PHASE OF TRIAL AND SEEK EXTERNAL PARTNER FOR CONTINUED DEVELOPMENT OF REPIBRESIB BRIDGEWATER, N.J., JULY 30, 2025 (GLOBE NEWSWIRE) -- VYNE THERAPEUTICS INC. (NASDAQ: VYNE) (VYNE OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING DIFFERENTIATED THERAPIES TO TREAT CHRONIC INFLAMMATORY AND IMMUNE-MEDIATED CONDITIONS WITH HIGH UNMET NEED, TODAY ANNOUNCED TOPLINE RESULTS FROM ITS PHASE 2B TRIAL EVALUATING REPIBRESIB GEL IN NONSEGMENTAL VITILIGO.

VYNE THERAPEUTICS ANNOUNCES TOPLINE RESULTS FROM PHASE 2B TRIAL WITH REPIBRESIB GEL IN NONSEGMENTAL VITILIGO

BRIDGEWATER, N.J., JULY 02, 2025 (GLOBE NEWSWIRE) -- VYNE THERAPEUTICS INC. (NASDAQ: VYNE) (VYNE OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING DIFFERENTIATED THERAPIES TO TREAT CHRONIC INFLAMMATORY AND IMMUNE-MEDIATED CONDITIONS WITH HIGH UNMET NEED, TODAY PROVIDED A PROGRAM UPDATE FOR VYN202 FOLLOWING THE CLINICAL HOLD ISSUED BY THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) IN APRIL FOR THE COMPANY'S PHASE 1B CLINICAL TRIAL IN THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS. VYN202 IS AN ORAL SMALL MOLECULE BD2-SELECTIVE BROMODOMAIN AND EXTRA-TERMINAL DOMAIN (BET) INHIBITOR THAT IS BEING DEVELOPED FOR THE TREATMENT OF IMMUNE-MEDIATED DISEASES.

VYNE THERAPEUTICS PROVIDES PROGRAM UPDATE ON ORAL BET INHIBITOR VYN202

REPIBRESIB GEL (VYN201) PHASE 2B VITILIGO TOP-LINE RESULTS EXPECTED IN MID-2025 EXPECTED CASH RUNWAY INTO 2H 2026 BRIDGEWATER, N.J., MAY 08, 2025 (GLOBE NEWSWIRE) -- VYNE THERAPEUTICS INC. (NASDAQ: VYNE) (VYNE OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING DIFFERENTIATED THERAPIES TO TREAT CHRONIC INFLAMMATORY AND IMMUNE-MEDIATED CONDITIONS WITH HIGH UNMET NEED, TODAY ANNOUNCED FINANCIAL RESULTS AS OF AND FOR THE QUARTER ENDED MARCH31, 2025, AND PROVIDED A BUSINESS UPDATE.

VYNE Therapeutics Inc.

VYNE

Price

Financial Reports

No items found.

Press Releases

VYNE Therapeutics Inc.

VYNE.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

VYNE